AstraZeneca Pharma to continue investing in R&D

They also plan to invest over zł.20 million in developing new drugs in Poland. At the end of 2003, the company, which only sells patented drugs, was ranked among the top ten in terms of value of sales to drugstores with a market share of about 2.6%. "We will carry out our annual plan under the condition that new patented drugs will appear on the refunded lists," said Jerzy Garlicki, president of AstraZeneca Pharma Poland. Almost a third of the company's 150 employees in Poland work in the research department, which has so far consumed zł.100 million since 1995. (Parkiet, p. 6) M.M.